The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... eloralintide and mazdutide. Several phase III data ...

Eli Lilly yesterday announced the decision to stop ... This decision to cease ongoing Phase III development of the schizophrenia treatment is expected to result in a third-quarter charge to ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

Eli Lilly has reportedly commenced Phase III clinical trials of oral medication, orforglipron, for weight loss in India. The oral drug is designed to provide an alternative to injectable weight ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Eli Lilly is to discontinue development of tabalumab for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) owing to disappointing results in two phase III trials.

US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Eli Lilly has released histological data from the Phase III VIVID-1 trial showing that its Crohn’s disease therapy Omvoh (mirikizumab) was superior to Johnson & Johnson’s (J&J) Stelara ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...